Singh Dhssraj, Gupta Kamal, Vacek James L
Division of Cardiovascular Diseases, Department of Internal Medicine, University of Kansas Hospital and Medical Center, Kansas City, KS.
Cleve Clin J Med. 2014 Feb;81(2):103-14. doi: 10.3949/ccjm.81a.13016.
Antiplatelet and anticoagulant drugs are the mainstay of treatment of acute coronary syndrome (ACS). The last 30 years have seen the development of various agents, a deeper understanding of the pathobiology of this disease, and an evolution in its treatment. We review the role of contemporary agents in ACS and highlight key clinical trials of these agents.
抗血小板和抗凝药物是急性冠状动脉综合征(ACS)治疗的主要手段。在过去30年里,出现了各种药物,对这种疾病的病理生物学有了更深入的了解,其治疗也有所发展。我们回顾了当代药物在ACS中的作用,并着重介绍了这些药物的关键临床试验。